http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022339171-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8742db8ce62f3324f6dbcbbd8aa91893
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-6615
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-6615
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
filingDate 2022-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4c42f59fe4eff05374aee5dbae2c9b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea5e5189e589c869d73dbc678c4c81c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a47a6df1b5ac909e2d6c56130f271e30
publicationDate 2022-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2022339171-A1
titleOfInvention Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascula calcification
abstract The present invention relates to compounds, pharmaceutical compositions, combined preparations, and dosage regimens for treating, inhibiting the progression, and preventing cardiovascular calcification, and in particular, coronary calcification, aortic artery calcification, and aortic valve calcification comprising inositol phosphates. In a particular aspect the disclosure provides a dosage regimen for treating, inhibiting the progression, or preventing cardiovascular calcification comprising the administration of about 200 mg to about 700 mg of myo-inositol hexaphosphate per administration.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021290642-A1
priorityDate 2019-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10010559-B2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456935922
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID478733249
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID478788473
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454705730
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465992738
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID478828178
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID161306539
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468387105
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID162245399
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID478828177

Total number of triples: 30.